Literature DB >> 26838062

[TAVI in Germany. What have we learned from current studies?].

N Mader1, T Rudolph2, S Baldus2, Th Wahlers3.   

Abstract

Transcatheter aortic valve implantation (TAVI) has become an established treatment for symptomatic aortic valve stenosis in inoperable patients and high-risk patients. In Germany the TAVI procedure has now surpassed the annual numbers of isolated surgical aortic valve replacement with a recent trend towards treatment of intermediate-risk patients; however, before TAVI can also be used in patients with lower surgical risk, studies are required to demonstrate the safety and efficacy of this method for this patient population.

Entities:  

Keywords:  Aortic valve replacement; Aortic valve stenosis; Complications; High-risk patients; Transcatheter aortic valve implantation

Mesh：

Year:  2016        PMID： 26838062     DOI： 10.1007/s00059-016-4406-8

Source DB:  PubMed          Journal:  Herz        ISSN： 0340-9937            Impact factor:   1.443


  23 in total

1.  Long-term durability of bioprosthetic aortic valves: implications from 12,569 implants.

Authors:  Douglas R Johnston; Edward G Soltesz; Nakul Vakil; Jeevanantham Rajeswaran; Eric E Roselli; Joseph F Sabik; Nicholas G Smedira; Lars G Svensson; Bruce W Lytle; Eugene H Blackstone
Journal:  Ann Thorac Surg       Date:  2015-02-04       Impact factor: 4.330

Review 2.  Update on transcatheter aortic valve replacement.

Authors:  Mohamed Abdel-Wahab; Mohamed El-Mawardy; Gert Richardt
Journal:  Trends Cardiovasc Med       Date:  2014-10-13       Impact factor: 6.677

Review 3.  Antithrombotic treatment in patients undergoing transcatheter aortic valve implantation (TAVI).

Authors:  Vincent J Nijenhuis; Naoual Bennaghmouch; Jan-Peter van Kuijk; Davide Capodanno; Jurriën M ten Berg
Journal:  Thromb Haemost       Date:  2015-02-05       Impact factor: 5.249

4.  Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description.

Authors:  Alain Cribier; Helene Eltchaninoff; Assaf Bash; Nicolas Borenstein; Christophe Tron; Fabrice Bauer; Genevieve Derumeaux; Frederic Anselme; François Laborde; Martin B Leon
Journal:  Circulation       Date:  2002-12-10       Impact factor: 29.690

Review 5.  Characterization of neurological injury in transcatheter aortic valve implantation: how clear is the picture?

Authors:  Jonathon P Fanning; Darren L Walters; David G Platts; Eamonn Eeles; Judith Bellapart; John F Fraser
Journal:  Circulation       Date:  2014-01-28       Impact factor: 29.690

6.  Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging.

Authors:  Alexander Ghanem; Andreas Müller; Claas P Nähle; Justine Kocurek; Nikos Werner; Christoph Hammerstingl; Hans H Schild; Jörg O Schwab; Fritz Mellert; Rolf Fimmers; Georg Nickenig; Daniel Thomas
Journal:  J Am Coll Cardiol       Date:  2010-02-24       Impact factor: 24.094

7.  Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study.

Authors:  Philipp Kahlert; Stephan C Knipp; Marc Schlamann; Matthias Thielmann; Fadi Al-Rashid; Marcel Weber; Uwe Johansson; Daniel Wendt; Heinz G Jakob; Michael Forsting; Stefan Sack; Raimund Erbel; Holger Eggebrecht
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

Review 8.  New conduction abnormalities after TAVI--frequency and causes.

Authors:  Robert M van der Boon; Rutger-Jan Nuis; Nicolas M Van Mieghem; Luc Jordaens; Josep Rodés-Cabau; Ron T van Domburg; Patrick W Serruys; Robert H Anderson; Peter P T de Jaegere
Journal:  Nat Rev Cardiol       Date:  2012-05-01       Impact factor: 32.419

Review 9.  The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties.

Authors:  Bernard Iung; Josep Rodés-Cabau
Journal:  Eur Heart J       Date:  2014-09-08       Impact factor: 29.983

Review 10.  The SAPIEN 3 valve: lights and shadows.

Authors:  M Facchin; M Mojoli; E Covolo; G Tarantini
Journal:  Minerva Med       Date:  2014-10-06       Impact factor: 4.806
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.